NCT06943755Phase 2, phase 3Recruiting

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Study sponsor: Exelixis

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-06-30Estimated
Enrollment · participants440Estimated
Source updated2026-10-30Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: Jun 2029. After: 30 Jun 2029.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview